Pomalidomide

For research use only. Not for use in humans.

製品コードS1567 別名:CC-4047

Pomalidomide化学構造

分子量(MW):273.24

Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs.

サイズ 価格(税別) 在庫  
10mM (1mL in DMSO) JPY 17100 あり
JPY 13600 あり
JPY 21900 あり
JPY 63400 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(39)

製品安全説明書

TNF-alpha阻害剤の選択性比較

生物活性

製品説明 Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs.
特性 A derivative of thalidomide and up to 10,000 times more potent than thalidomide.
ターゲット
TNF-α [1]
(PBMCs)
13 nM
体外試験

Pomalidomide inhibits lipopolysaccharide (LPS) stimulated TNF-alpha release in human PBMC and in human whole blood with IC50 values of 13 nM and 25 nM, respectively. [1] Pomalidomide inhibits the growth of T regulatory cells which is stimulated by IL-2 with an IC50 of ~1 μM. [2] Treatment with Pomalidomide (6.4 nM-10 μM) increases the production of IL-2 in human peripheral blood T cells, and is slightly more potent in the CD4+ subset than in the CD8+ subset. Pomalidomide is significantly more potent than CC-5013 at elevating IL-2, IL-5, and IL-10 levels, but only slightly more potent than CC-5013 at elevating IFN-γ levels. Pomalidomide enhances SEE and Raji cells induced AP-1 transcriptional activity in Jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μM. [3] Exposure of Raji cells to various concentrations of Pomalidomide (2.5-40 μg/mL) for 48 hours leads to a significant decrease in cell proliferation and DNA synthesis. There is a reduction of ~40% compared to vehicle-treated controls. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLP-8 NWLkcGw1S3m2b4TvfIlkcXS7IFHzd4F6 NFL1OIcyOCEQvF2= NFPEVVgzPCCq MVjwc5RmdnSueTDheYdu\W62czDkbZJm[3RiYX7kJIlv\Gm{ZXP0JG1OKGOnbHygb4ltdGmwZzDifUBUSVJ? MoTvNlY{Ozh{N{O=
J-CD38 M3fVXGN6fG:2b4jpZ4l1gSCDc4PhfS=> MUCxNEDPxE1? NXu3NJkzOjRiaB?= M2C0TpBwfGWwdHz5JIF2\22nboTzJIRqemWldDDhcoQhcW6maYLlZ5QhVU1iY3XscEBscWyuaX7nJIJ6KFODUh?= MlnsNlY{Ozh{N{O=
R-CD38 MlnaR5l1d3SxeHnjbZR6KEG|c3H5 NHHlSYYyOCEQvF2= NF;rWYIzPCCq MXPwc5RmdnSueTDheYdu\W62czDkbZJm[3RiYX7kJIlv\Gm{ZXP0JG1OKGOnbHygb4ltdGmwZzDifUBUSVJ? NXHzdpVHOjZ|M{iyO|M>
BC-3 NHyzTpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX1VZI{QS1zMkWwJI5O MWO1JIQ> M2\MWGROW00EoB?= NUTJXG5rUUN3ME2xNFchdk1uIHnubIljcXS|IHPlcIwhUUN3ME2xNFchdk1uII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MYCyOlEyQTl|OR?=
BCBL-1 NYXqVYdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXezPU0yOjVyIH7N NHu4cZI2KGR? NGLBZ5BFVVORwrC= Ml3YTWM2OD15NDDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NGjHSJMzPjFzOUmzPS=>
JSC-1 MoPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHjbVA{QS1zMkWwJI5O NXjmN5hxPSCm MmHHSG1UV8Li NV7kS4ZVUUN3ME2zOEBvVSxiaX7obYJqfHNiY3XscEB3cWGkaXzpeJkh\G:|ZTDk[ZBmdmSnboTsfS=> M2G0OlI3OTF7OUO5
VG-1 NV;BVWlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXOzPU0yOjVyIH7N NFnvbIU2KGR? MWLEUXNQyqB? NHPjfY1KSzVyPUGwNUBvVSxiaX7obYJqfHNiY3XscEB3cWGkaXzpeJkh\G:|ZTDk[ZBmdmSnboTsfS=> NWfBOYZQOjZzMUm5N|k>
UMPEL-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfWd2M{QS1zMkWwJI5O M4rGblUh\A>? NHrxNJVFVVORwrC= MWHJR|UxRTN{IH7NMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NWr4TlJCOjZzMUm5N|k>
UMPEL-3 NUHkVpRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXVPIk{QS1zMkWwJI5O MoCxOUBl M2iwTWROW00EoB?= MYHJR|UxRTFzMTDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NXzpbYpmOjZzMUm5N|k>
BC-1 NEnRcWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuzPU0yOjVyIH7N MorlOUBl NFPRW2pFVVORwrC= MmLWTWM2OD15NESgcm0tKGmwaHnibZR{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= M2HMSlI3OTF7OUO5
BCP-1 NIjP[Y1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHGN|kuOTJ3MDDuUS=> MmLOOUBl MYDEUXNQyqB? M4j6bGlEPTB;M{m2JI5ONCCrbnjpZol1eyClZXzsJJZq[WKrbHn0fUBld3OnIHTldIVv\GWwdHz5 MofYNlYyOTl7M{m=
APK-1 NXHLWFhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17pUVM6NTF{NUCgcm0> Mn21OUBl M{O0eWROW00EoB?= M4XaO2lEPTB;MkK2JI5ONCCrbnjpZol1eyClZXzsJJZq[WKrbHn0fUBld3OnIHTldIVv\GWwdHz5 NVqyWXd7OjZzMUm5N|k>
RPMI8226  MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSwMlAyNTVyIN88US=> NVXiWZpXPDhiaB?= Mmm5SG1UV8Li MknnTWM2OD16IN88US=> M3u5eFI3ODl5OEey
OPM2  MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr4c5ExNjBzLUWwJO69VQ>? M1;oTFQ5KGh? MV3EUXNQyqB? M{nUVWlEPTB;MUCg{txO NWiyT5RXOjZyOUe4O|I>
RPMI8226  NEjwV5pHfW6ldHnvckBCe3OjeR?= MUexNEDPxE1? M1nCb|Q5KGh? M3O2N2ROW00EoB?= MmnKd5Rz\W6pdHjlcpMh[3m2b4DsZZNucWNvboXjcIVieiC|aIX0eIxqdmdib3[gcXRQWiCjbnSgdE1uXE:UIIDyc5RmcW5? NYP3RZNuOjZyOUe4O|I>
OPM2  MVzGeY5kfGmxbjDBd5NigQ>? NG\TOYwyOCEQvF2= NY[xSnlRPDhiaB?= M3zRdmROW00EoB?= NUDmW25Ee3S{ZX7neIhmdnNiY4n0c5Bt[XOvaXOtcpVkdGWjcjDzbJV1fGyrbnegc4YhdVSRUjDhcoQheC2vVF;SJJBzd3SnaX6= Mn3VNlYxQTd6N{K=
RPMI8226 MX7GeY5kfGmxbjDBd5NigQ>? NXrs[pNDOC5zLUGwJO69VQ>? NGX4fII1KGh? NHTNemNFVVORwrC= NWnz[nB{cW6lcnXhd4V{KF[HR1[gcXJPSSCneIDy[ZN{cW:w MWOyOVA2Ozl7MB?=
SH-SY5Y  M3HnS2Fxd3C2b4Ppd{BCe3OjeR?= M4HmWFI2yqEQvHevcWw> NIrWVVgyyqCq Mli2Z4F2e2W|IIP0ZZRqe3SrY3HscJkhe2mpbnnmbYNidnRicnXkeYN1cW:wIHnuJIJwfGhiQ2DGMUBidmRiQ2DGL2NONWmwZIXj[YQh[XCxcITvd4l{yqB? M4\Nd|I1QTd3Mke2
JJN3 M1rRU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3z3dlAvOS1zMECg{txO NYT3O4ZIPzJiaB?= M2jGOGROW09? NHH0UGdqdmirYnn0d{Bk\WyuIHfyc5d1cCC|bHnnbJRtgQ>? NUPv[otoOjNzN{izO|g>
XG-1 NYTNO2ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjkOIZOOC5zLUGwNEDPxE1? MmrrO|IhcA>? Ml\0SG1UVw>? NHXsXXhqdmirYnn0d{Bk\WyuIHfyc5d1cA>? MWWyN|E4QDN5OB?=
CD138+  NFrHVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGqxTHYxNjFvMUCwJO69VQ>? NGTXdpE4OiCq NGGyNlBFVVOR NE\iOmlqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NHz0SIYzOzF5OEO3PC=>
XG-1 MWHGeY5kfGmxbjDBd5NigQ>? MnraNk8yODBizszN MYSyOEBp NVjXTIxoTE2VTx?= MoHpbY5pcWKrdIOgR2NNOy:PSWCtNe6yKG2UTlGg[ZhxemW|c3nvci=> MlvJNlMyPzh|N{i=
U266 Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVX1cIl1OC5yMT2xNEDPxE1? MkfzOFjjiImq Ml7QSG1UVw>? NEG3fI9qdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MmLRNlI2PTJyMEi=
CRBN60 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof6NE4xOS1zMDFOwG0> NF76XpY1QOLCiXi= M3PXRWROW09? M17m[IlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NVHnbll[OjJ3NUKwNFg>
CRNB75 M175UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPSNE4xOS1zMDFOwG0> M2i5cVQ56oDLaB?= MY\EUXNQ MVzpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 Mkj6NlI2PTJyMEi=
MM.1S M{\mb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTReWYxNjBzLUGwJO69VQ>? M2[wSlQ56oDLaB?= NFjaR29FVVOR NFn6Z4J{cWewaX\pZ4FvfGy7IHnubIljcXS|IIDyc4xq\mW{YYTpc44h[XRiY3;uZ4VvfHKjdHnvcpMh[XNibH;3JIF{KDBwMEJOwG0> NVL6[Y11OjF|OEmzNlc>
OPM2 NHzPWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;0WlkxNjBzLUGwJO69VQ>? M4nKV|Q56oDLaB?= M1fqdWROW09? NVvDelRQe2mpbnnmbYNidnSueTDpcohq[mm2czDwdo9tcW[ncnH0bY9vKGG2IHPvcoNmdnS{YYTpc45{KGG|IHzve{BieyByLkCx{txO NH;pT5QzOTN6OUOyOy=>
MM.1S MmLUSpVv[3Srb36gRZN{[Xl? NIDvfm8yOCEQvF2= NX3QNJBLPzJiaB?= NYqwT29STE2VTx?= NFW5eFR{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUheHKxdHXpckBt\X[nbDDv[kBEN0WEUN8yJIl{d2[xcn3zxsA> Mk\INlE{QDl|Mke=
H929 NEjqXm5HfW6ldHnvckBCe3OjeR?= NXHUNZp2OTBizszN NHj2[WU4OiCq NHXCU4dFVVOR M{npe5Nq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBxem:2ZXnuJIxmfmWuIH;mJGMwTUKSzsKgbZNw\m:{bYRCpC=> MknjNlE{QDl|Mke=
OPM2 M{LMTGZ2dmO2aX;uJGF{e2G7 NXnYNpl7OTBizszN MUm3NkBp NG\EcWNFVVOR NYC5WoVHe2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXygc4YhSy:HQmFOtkBqe2:ob4Ltd:Kh MWGyNVM5QTN{Nx?=
CT26 MVXGeY5kfGmxbjDBd5NigQ>? NVj6b3dMOS9zMDFOwG0> MnXtNlQhcA>? MYry[YR2[2W|IITo[UBvfW2kZYLzJI9nKGyrdnWgZ49td26rZYRCpC=> NG\ySJEyQTZ|OEm3Oy=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
CEBPβ; 

PubMed: 21389327     


MM.1S, H929, OPM2, or primary myeloma cells were cultured with DMSO, pomalidomide, or lenalidomide at the indicated concentrations for 3 days. Representative results from 3 independent experiments are shown. Cells were then lysed, and cell lysates were an䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ

IKZF1 / IKZF3 / UBE2G1 / CRBN ; 

PubMed: 30234487     


Immunoblot analysis of SKMM2 cells transduced with lentiviral vectors encoding GFP, UBE2G1 and UBE2G1-C90S. Cells were treated with DMSO vehicle control, LEN or POM at the indicated concentrations for 16 hr.

21389327 30234487
Immunofluorescence
IKZF1; 

PubMed: 29496670     


CD34+ cells were treated with DMSO (0.01%), LEN, or POM (1 μM) for 6 hours. The cells were then fixed and stained for IKZF1 (red color), and nuclear counterstaining was performed with DAPI (blue color). The localization of IKZF1 was observed using a Leica䲧疝Ỵ疞㧀疜膉痘 

29496670
体内試験 Pomalidomide enhances the antitumor effect of rituximab against B-cell lymphomas in severe combined immunodeficient mice. Administration of Pomalidomide in combination with rituximab, gives the mice a median survival period of 74 days compared with 58 days of CC5013/rituximab treatment and 45 days of rituximab nonotherapy. The synergistic effect of Pomalidomide and rituximab can be completely abrogated by depletion of NK cells, supporting the proposal that NK cell expansion is one mechanism by which Pomalidomide may augment rituximab antitumor activity. [4]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
- 合併

Inhibition of TNF-α synthesis:

TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC. Pomalidomide is added to human PBMCs 1 hour prior to the addition of LPS (1 μg/mL) and incubation continued for an additional 18-20 hours. Supernatants are then harvested, and the concentration of TNF-α in the supernatants is determined by ELISA. The concentration of Pomalidomide that inhibits TNF- production by 50% (IC50) is calculated by nonlinear regression analysis. The human whole blood TNF- inhibition assay is run in a similar fashion to the PBMC assay except that heparinized fresh human whole blood is plated directly into microtiter plates.
細胞試験: [4]
- 合併
  • 細胞株: Raji, SU-DHL-4 and SU-DHL-10 cell lines
  • 濃度: Dissolved in DMSO, final concentrations 2.5-40 μg/mL
  • 反応時間: 24 or 48 hours
  • 実験の流れ: For assessment of cell apoptosis, Lymphoma cell lines are exposed to Pomalidomide (5 μg/mL) for 24 hours or 48 hours. The cells are stained with FITC-labeled Annexin V and propidium iodine. Cell apoptosis is analyzed by multicolor flow cytometric analysis using a fluorescence-activated cell sorter/FACStar Plus flow cytometer. Cells are scored as apoptotic if they are Annexin V–positive and propidium iodine–negative/positive (early and late apoptosis, respectively). For determination of cell proliferation, the Lymphoma cell lines are exposed to Pomalidomide (2.5, 5, 10, 20, and 40 μg/mL) for 24 hours or 48 hours. 1 μCi per well (96-well plate) of [3H]-thymidine is added and cells are incubated for another 18 hours. Cells are then harvested using the Harvest system into the 96-well glass filters and [3H]-thymidine uptake is measured using an automated scintillation counter.
    (参考用のみ)
動物試験:[4]
- 合併
  • 動物モデル: Disseminated lymphoma-bearing SCID mice
  • 製剤: Dissolved in DMSO to make a 10 mg/mL stock solution and diluted to a final concentration of 1 mg/mL in sterile 0.9% normal saline.
  • 投薬量: 0.5 mg/kg
  • 投与方法: Injection i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 54 mg/mL (197.62 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
3mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 273.24
化学式

C13H11N3O4

CAS No. 19171-19-8
保管
in solvent
別名 CC-4047
Smiles NC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03798314 Recruiting Biological: Nivolumab|Drug: Pomalidomide Recurrent Nervous System Lymphoma|Recurrent Primary Vitreoretinal DLBCL|Refractory Nervous System Lymphoma|Refractory Primary Vitreoretinal DLBCL Mayo Clinic|National Cancer Institute (NCI) January 30 2019 Phase 1
NCT03567616 Suspended Drug: Venetoclax|Drug: Pomalidomide|Drug: Dexamethasone Multiple Myeloma AbbVie|Celgene October 18 2018 Phase 2
NCT03683277 Not yet recruiting Drug: Ixazomib/Pomalidomide/Dexamethasone Multiple Myeloma|Relapsed and Refractory Multiple Myeloma|Genetic Condition Intergroupe Francophone du Myelome|AXONAL|Nantes University Hospital|University Hospital Grenoble|EURAXI October 1 2018 Phase 2
NCT03113942 Active not recruiting Drug: Pomalidomide 2 MG Oral Capsule [Pomalyst] High Grade Squamous Intra-epithelial Lesion (HSIL) Kirby Institute June 14 2017 Phase 2
NCT03015922 Recruiting Drug: Lenalidomide or Pomalidomide|Biological: REOLYSIN Multiple Myeloma University of Leeds|Myeloma UK|Oncolytics Biotech|Celgene Corporation June 5 2017 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is S1567 in the 1% DMSO+30% polyethylene glycol+1% Tween 80 suitable for oral administration?

  • 回答:

    S1567 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension. This formulation is for oral gavege.

  • 質問2:

    I would like to know if the pomalidomide is racemic or optically active?

  • 回答:

    Our S1567 Pomalidomide is racemic.

TNF-alphaシグナル伝達経路

TNF-alpha Inhibitors with Unique Features

相関TNF-alpha製品

Tags: Pomalidomideを買う | Pomalidomide ic50 | Pomalidomide供給者 | Pomalidomideを購入する | Pomalidomide費用 | Pomalidomide生産者 | オーダーPomalidomide | Pomalidomide化学構造 | Pomalidomide分子量 | Pomalidomide代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID